Grandfield & Dodd, LLC Neurocrine Biosciences Inc Transaction History

Grandfield & Dodd, LLC

$1.53 Billion
Q1 2025

A detailed history of Grandfield & Dodd, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 16,570 shares of NBIX stock, worth $1.82 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

16,570

Previous 16,111 2.85%

Holding current value

$1.82 Million

Previous $2.2 Million 16.69%

% of portfolio

0.12%

Previous 0.14%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 02, 2025	BUY	$107.22 - $153.29 $49,213 - $70,360	459 Added 2.85%	16,570 $1.83 Million
Q4 2024 Feb 06, 2025	BUY	$111.62 - $139.44 $32,369 - $40,437	290 Added 1.83%	16,111 $2.2 Million
Q3 2024 Nov 08, 2024	BUY	$114.58 - $153.15 $32,082 - $42,882	280 Added 1.8%	15,821 $1.82 Million
Q2 2024 Aug 09, 2024	SELL	$130.86 - $143.19 $6,935 - $7,589	-53 Reduced 0.34%	15,541 $2.14 Million
Q1 2024 May 03, 2024	BUY	$130.4 - $143.74 $26,471 - $29,179	203 Added 1.32%	15,594 $2.15 Million
Q4 2023 Jan 31, 2024	BUY	$106.07 - $132.76 $20,789 - $26,020	196 Added 1.29%	15,391 $2.03 Million
Q3 2023 Oct 25, 2023	SELL	$94.02 - $117.1 $5,641 - $7,026	-60 Reduced 0.39%	15,195 $1.71 Million
Q2 2023 Aug 07, 2023	BUY	$89.53 - $104.87 $6,893 - $8,074	77 Added 0.51%	15,255 $1.44 Million
Q1 2023 Apr 28, 2023	BUY	$94.11 - $123.02 $25,786 - $33,707	274 Added 1.84%	15,178 $1.54 Million
Q4 2022 Jan 20, 2023	BUY	$106.72 - $127.06 $66,700 - $79,412	625 Added 4.38%	14,904 $0
Q3 2022 Nov 03, 2022	BUY	$92.03 - $107.81 $32,394 - $37,949	352 Added 2.53%	14,279 $1.52 Million
Q2 2022 Aug 01, 2022	BUY	$75.79 - $100.07 $9,852 - $13,009	130 Added 0.94%	13,927 $1.36 Million
Q1 2022 Apr 19, 2022	BUY	$72.45 - $94.81 $41,006 - $53,662	566 Added 4.28%	13,797 $1.29 Million
Q4 2021 Feb 08, 2022	BUY	$79.65 - $106.22 $105,456 - $140,635	1,324 Added 11.12%	13,231 $1.13 Million
Q3 2021 Oct 28, 2021	BUY	$86.18 - $99.03 $14,133 - $16,240	164 Added 1.4%	11,907 $1.14 Million
Q2 2021 Jul 28, 2021	BUY	$89.43 - $102.27 $16,991 - $19,431	190 Added 1.64%	11,743 $1.14 Million
Q1 2021 Apr 22, 2021	BUY	$87.57 - $119.4 $15,237 - $20,775	174 Added 1.53%	11,553 $1.12 Million
Q4 2020 Jan 29, 2021	BUY	$86.91 - $108.33 $22,770 - $28,382	262 Added 2.36%	11,379 $1.09 Million
Q3 2020 Nov 03, 2020	BUY	$96.16 - $135.15 $7,788 - $10,947	81 Added 0.73%	11,117 $1.07 Million
Q2 2020 Jul 24, 2020	BUY	$85.09 - $130.36 $51,054 - $78,216	600 Added 5.75%	11,036 $1.35 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $32,297 - $48,916	430 Added 4.3%	10,436 $903,000
Q4 2019 Feb 07, 2020	BUY	$86.8 - $118.57 $46,872 - $64,027	540 Added 5.7%	10,006 $1.08 Million
Q3 2019 Oct 30, 2019	BUY	$83.82 - $101.5 $71,666 - $86,782	855 Added 9.93%	9,466 $853,000
Q2 2019 Jul 29, 2019	BUY	$72.24 - $91.27 $52,735 - $66,627	730 Added 9.26%	8,611 $727,000
Q1 2019 Apr 26, 2019	BUY	$69.31 - $91.53 $4,227 - $5,583	61 Added 0.78%	7,881 $694,000
Q4 2018 Feb 12, 2019	BUY	$68.32 - $124.36 $4,440 - $8,083	65 Added 0.84%	7,820 $558,000
Q3 2018 Nov 02, 2018	BUY	$98.88 - $125.85 $6,921 - $8,809	70 Added 0.91%	7,755 $953,000
Q2 2018 Jul 27, 2018	BUY	$75.3 - $105.99 $3,012 - $4,239	40 Added 0.52%	7,685 $755,000
Q1 2018 May 04, 2018	SELL	$75.88 - $92.43 $20,487 - $24,956	-270 Reduced 3.41%	7,645 $634,000
Q4 2017 Feb 06, 2018	BUY	$58.53 - $77.59 $17,851 - $23,664	305 Added 4.01%	7,915 $614,000
Q3 2017 Nov 03, 2017	BUY	$47.97 - $61.28 $365,051 - $466,340	7,610	7,610 $466,000

Others Institutions Holding NBIX

# of Institutions

646

Shares Held

94.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.

Account

Grandfield & Dodd, LLC Neurocrine Biosciences Inc Transaction History